Viatris Third Quarter 2026 Financial Results - VIATRIS INC

Financial Performance:

• Q3 2026 total revenue was $3.75 billion, with full-year YTD revenue up 2% operationally, adjusted EBITDA up 6%, and adjusted EPS up 8%.
• Adjusted gross margin reached 58% in Q3, driven by high-margin growth in North America and Greater China, offsetting supply constraints in Europe.
• Free cash flow for Q3 was $814 million ($895 million excluding transaction/restructuring costs); cumulative YTD capital return was $717 million via $300M buybacks and dividends.
• Gross leverage stood at 2.9x, remaining below the long-term target range of 2.8x–3.2x.
• A $100 million revenue headwind in Q3 was attributed to supply constraints at the Neshic facility in Europe and emerging markets.

Guidance and Future Outlook:

• Full-year 2026 guidance was raised across all key metrics to a midpoint reflecting 2% revenue growth, 6% EBITDA growth, and 8% EPS growth operationally.
• Q4 outlook includes continued US strength, accelerated supply for estradiol patches, China growth moderation due to procurement policies, and an additional ~$100M revenue impact from supply disruptions.
• Management expressed confidence that $5 billion EBITDA could be achieved by 2027 (previously a 2030 target) due to base business momentum and the Pacira acquisition.
• The acquisition of Pacira is expected to close before end of November, with financial impact immediately creditable to 2027 results; transaction will be funded by cash and debt with minimal impact on leverage.
• Projected annual cost synergies of >$50M to be realized by end of 2028 from the Pacira deal.

Business Segments and Product Lines:

• North America: Sales grew ~7% driven by complex generics (estradiol patches volumes doubled) and new launches (Winlow, Winlows); shifting portfolio mix toward higher-margin products.
• Greater China: Sales grew ~10% despite hospital procurement policies, supported by cardiovascular portfolio and e-commerce channel growth.
• Japan: Sales declined YoY due to government price regulations but remain positioned for growth with the upcoming launch of Wacox (approval received) and uptake of Spidea.
• Innovative Medicine Pipeline: Fast-acting meloxicam (NDA review complete, PDUFA Dec 27); Rizum-V approved for presbyopia; Phase 3 readouts for Sineramod and Ciladogrel expected H1 2027; one-time monthly aripiprazole injection launched in US; first-to-file status secured for Wegovy (semaglutide) 25mg tablets.
• Pacira Acquisition: Adds patent-protected drugs Expirel and Zolretta, expected to drive US innovative medicines revenue to >$1B in 2027; brings US commercial infrastructure for non-opioid pain management.

Market and Competitive Landscape:

• US transdermal HRT market demand is surging (unanticipated growth) due to removal of FDA black box warnings and GLP-1 induced delayed gastric emptying favoring patches; <30% of symptomatic women currently treated, representing significant untapped potential.
• Competition in Europe and emerging markets is intensifying, with specific product pressures noted, while North America shows accelerating momentum.
• GLP-1 generic pipeline is competitive; company secured first-to-file for semaglutide and has developed a portfolio covering multiple presentations of semaglutide and tirzepatide.
• In Japan, generic entry for Xarelto is expected in 2030 (volume-limited), but IP expansion and lifecycle management are anticipated to sustain value.

Risks and Challenges:

• Supply chain disruption at the Neshic facility remains a key risk, currently classified as OAI (Official Action Indicated) with ongoing remediation and production suspension.
• Policy headwinds in China (hospital procurement) and Japan (price regulations) are moderating growth rates compared to historical levels.
• Loss of Exclusivity (LOE) risks identified: Ametiza in Japan (mid-2027) and Isosulfam Blue in the US.
• Generic competition for Xarelto remains a long-term threat, though manufacturing barriers and IP litigation are viewed as defensive factors.
• Execution risk on integrating Pacira's capabilities and realizing stated synergies.

Management Commentary and Tone:

• Management tone is highly confident, describing the business as entering a "new phase of sustained growth" with disciplined strategy execution.
• CEO Scott Smith highlighted the "balanced view" of 2026 and strong positioning for 2027, emphasizing the strategic value of the Pacira deal.
• Interim CFO Paul Campbell emphasized financial discipline, improved operating leverage, and the neutral revenue impact of supply issues vs. margin expansion.
• Leadership transition noted: Peter McCormick retired; Paul Duffy appointed as new Chief Supply Officer to address manufacturing challenges.

Analyst Questions and Answers:

• China Growth: Q3 10% growth was slightly above expectations; policy impact is moderate but expected to increase in Q4, with growth returning to low-mid single digits in 2027.
• EBITDA Acceleration: Analysts asked if $5B EBITDA is possible by 2027; Management confirmed this is "in the ballpark" given momentum and acquisition synergies.
• HRT Market Size: Management cited 45M asymptomatic women in the US, with plans to expand from 1.5M patients (2026) to 2.5M (2027) using their patches.
• Pipeline Timing: Sineramod and Ciladogrel readouts expected H1 2027; Fast-acting meloxicam approval expected Dec 27.
• Xarelto Strategy: Management plans to vigorously defend IP post-2030 generic entry, leveraging lifecycle management capabilities.
• Pricing for Fast-Acting Meloxicam: Focused on outpatient/retail settings; pricing models are being explored but no final decisions made pending label finalization.

Other Key Points:

• The company continues to execute a "complex generics" strategy, moving away from commodity generics to higher-margin, stickier revenue streams (e.g., estradiol patches).
• A strategic review is on track to deliver $120M in net savings for the year.
• The acquisition of Pacira is viewed as a catalyst to accelerate the innovative medicines strategy and establish a leadership position in non-opioid pain management.
• First-to-file status for semaglutide 25mg tablets strengthens the generic GLP-1 portfolio for the US market.